Caryn Peterson Joins ASPEN Neuroscience Board of Directors
SAN DIEGO, June 22, 2021 — Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson’s disease (PD), announced today that Caryn Peterson, executive vice president of Regulatory Affairs for Gossamer Bio, has joined the Aspen Board of Directors. “We welcome Caryn as an important addition to our
Learn MoreAspen Neuroscience announces appointment of Damien McDevitt, PhD as President and Chief Executive Officer
SAN DIEGO, January 25, 2021 — Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson’s disease, announced today that it has appointed biotech leader Damien McDevitt, PhD, as President and Chief Executive Officer. Dr. McDevitt will also be joining the company’s board of directors. “We are excited to
Learn MoreAspen Neuroscience to Present at 2020 Virtual Cell & Gene Meeting on the Mesa
SAN DIEGO, October 5, 2020 — Aspen Neuroscience announced today that Howard Federoff, MD, PhD, Chief Executive Officer, will present at the annual Cell & Gene Meeting on the Mesa to be held virtually October 12-16, 2020. Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a five-day
Learn MoreAspen Neuroscience announces management transition
SAN DIEGO, Aug. 3, 2020 /PRNewswire/ – Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson’s disease, today announced that Dr. Jeanne Loring, co-founder and Chief Scientific Officer, will transition to the role of Special Advisor to the Company’s Research and Development Committee. Dr. Loring is Professor emeritus
Learn MoreAspen Neuroscience Announces Reconstitution of the Board of Directors with the Addition of Seasoned Industry Executives
SAN DIEGO, April 6, 2020 — Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson disease, today announced the reconstitution of its Board of Directors, including a new Board Chair, following the closing of its Series A financing of $70 million.
Learn MoreAspen Neuroscience Announces $70 Million Series A Financing Led by OrbiMed to Advance Development of the First Autologous Neuron Replacement Therapy to Treat Parkinson Disease
SAN DIEGO, Apr. 1, 2020 /PRNewswire/ — Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson’s disease, today announced the close of its Series A funding round of $70 million. OrbiMed led the investment round with participation from ARCH Venture Partners, Frazier Healthcare Partners, Domain Associates, Section 32, and Sam Altman.
Learn MoreAspen Neuroscience announces board of directors and scientific advisory board
SAN DIEGO, Jan. 9, 2020 /PRNewswire/ — Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson disease, has announced the members of its Board of Directors and Scientific Advisory Board. These boards bring together many of the world’s most distinguished industry and academic minds to deliver Aspen’s personalized cell therapy to persons suffering with Parkinson disease.
Learn MoreAspen Neuroscience Launches With $6.5 Million Seed Funding to Advance First-of-its-Kind Personalized Cell Therapy for Parkinson’s Disease
SAN DIEGO, Dec. 12, 2019 /PRNewswire/ — Aspen Neuroscience, Inc. today announced its launch following a $6.5 million seed round — led by Domain Associates and Axon Ventures and including Alexandria Venture Investments, Arch Venture Partners, OrbiMed and Section 32 — to develop the first autologous cell therapies for Parkinson’s disease.
Learn MoreFirst-in-kind Human 3-dimensional Models of Parkinson’s Disease and Progressive Multiple Sclerosis Launching to the International Space Station
LOUISVILLE, December 02, 2019, 10:00 AM EST — (BUSINESS WIRE) — The National Stem Cell Foundation (NSCF) announced today that research teams from Aspen Neuroscience and the New York Stem Cell Foundation (NYSCF) Research Institute will send a first-in-kind study of neurodegenerative disease to the International Space Station (ISS) on the nineteenth SpaceX Commercial Resupply Services (CRS-19) mission, scheduled to launch December 4th from the Kennedy Space Center in Cape Canaveral, Florida.
Learn More